- Home
- MRSN vs RDI Comparison
MRSN vs RDI Comparison
Compare MRSN & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- RDI
- Stock Information
- Founded
- MRSN 2001
- RDI 1937
- Country
- MRSN United States
- RDI United States
- Employees
- MRSN N/A
- RDI N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- RDI Movies/Entertainment
- Sector
- MRSN Health Care
- RDI Consumer Discretionary
- Exchange
- MRSN Nasdaq
- RDI Nasdaq
- Market Cap
- MRSN 37.0M
- RDI 35.7M
- IPO Year
- MRSN 2017
- RDI N/A
- Fundamental
- Price
- MRSN $7.66
- RDI $1.52
- Analyst Decision
- MRSN Strong Buy
- RDI
- Analyst Count
- MRSN 3
- RDI 0
- Target Price
- MRSN $33.00
- RDI N/A
- AVG Volume (30 Days)
- MRSN 90.2K
- RDI 71.5K
- Earning Date
- MRSN 08-13-2025
- RDI 08-14-2025
- Dividend Yield
- MRSN N/A
- RDI N/A
- EPS Growth
- MRSN N/A
- RDI N/A
- EPS
- MRSN N/A
- RDI N/A
- Revenue
- MRSN $34,769,000.00
- RDI $219,213,000.00
- Revenue This Year
- MRSN N/A
- RDI $5.21
- Revenue Next Year
- MRSN N/A
- RDI $11.45
- P/E Ratio
- MRSN N/A
- RDI N/A
- Revenue Growth
- MRSN 16.14
- RDI 7.59
- 52 Week Low
- MRSN $5.21
- RDI $1.17
- 52 Week High
- MRSN $70.75
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- MRSN 54.20
- RDI 56.80
- Support Level
- MRSN $6.63
- RDI $1.47
- Resistance Level
- MRSN $7.25
- RDI $1.59
- Average True Range (ATR)
- MRSN 0.52
- RDI 0.08
- MACD
- MRSN 0.02
- RDI -0.00
- Stochastic Oscillator
- MRSN 65.86
- RDI 60.61
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.